Edgewise Therapeutics, Inc. maintains a Buy rating, driven by favorable interim 12-week safety data for EDG-7500 in phase 2 CIRRUS-HCM and multiple 2026 catalysts. EDG-7500 demonstrated strong tolerability and no clinically meaningful LVEF reductions, potentially differentiating it from cardiac myosin inhibitors for HCM treatment. Key 2026 catalysts include phase 2 CIRRUS-HCM efficacy data in Q2 2026 and potential phase 3 initiation for EDG-7500 in Q4 2026, targeting both oHCM and nHCM patients.

With CHRW shares moving north, we assess the current positioning of the stock to determine if it's a good investment at this juncture.

DVY is a US equity ETF with a dividend focus with a TER of 0.38%. It has an A dividend grade from SA, due to competitive distributions and positive CAGR. It has a good anchoring to the US market in terms of price return, which in my opinion makes it good for portfolio strategies.

Robinhood Chief Investment Officer Stephanie Guild joins 'Power Lunch' to talk what is ahead for teh bull market in 2026, retail investing trends, and more.

M&T Bank Corporation MTB has been witnessing a steady growth in its net interest income (NII) over the past few years. Over the past five years (ending 2024), NII registered a compound annual growth rate (CAGR) of 15.4%.

USB is up nearly 22% in six months, do strong revenue growth, liquidity, and digital investments make it a buy, hold, or sell now? Let us discuss.

Zeta Global offers a compelling opportunity as an underappreciated marketing intelligence software company with accelerating organic revenue growth and improving valuation multiples. ZETA's aggressive FY28 framework targets a 20% revenue CAGR and 28% adjusted EBITDA CAGR, supported by AI-driven product differentiation and strong Fortune 100 customer penetration. With FY25 guidance raised to $1.275 billion in revenue (+27% y/y) and $273.7 million in adjusted EBITDA, ZETA trades at just 17.8x FY25 and 13.8x FY26 EV/EBITDA.

Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares. Attachment Alvotech Own Shares Notification 29 Dec 2025

Dell Technologies Inc (NYSE:DELL) stock is down 1.4% to trade at $127.37, set to snap a five-day win streak as tech sector headwinds weigh.

The company looked to be in an unfixable decline when he took over in 1993—and changed its focus from hardware to services.

Sam Vadas talks about the numerous headlines surrounding A.I. giant Nvidia (NVDA) after it spent $5 billion total on millions Intel (INTC) shares.

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Regulation used to be something companies argued with. Delayed. Negotiated.

Gold posts largest one-day loss since October. Technical analysis shows trapped longs could drive prices to $4,041 swing target by January 6.

Marathon Petroleum (MPC) shares have declined by 13.8% over the course of 21 trading days. The recent decrease is driven by renewed worries regarding its Q3 earnings shortfall and high maintenance expenses, yet significant declines like this often lead to a more challenging question: is this weakness a temporary situation, or does it indicate more profound issues within the company?

After 9 months of battle-testing with real market data, IKIGAI Academy graduates its first two certified cohorts—with Batches 2 and 3 already sold out. Learn more on With Q. After 9 months of battle-testing with real market data, IKIGAI Academy graduates its first two certified cohorts—with Batches 2 and 3 already sold out. Learn more on With Q.

Perimeter Medical Imaging AI, Inc. (PINK:CA) Shareholder/Analyst Call Prepared Remarks Transcript

IREN (NASDAQ:IREN) looked like an unstoppable growth stock from April to the end of October, gaining more than 1,000% during that stretch.

LOS ANGELES, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 23, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired StubHub Holdings, Inc. (“StubHub” or the “Company”) (NYSE: STUB) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company's September 2025 initial public offering (“IPO” or the “Offering”).

Procter & Gamble leans on Focus Markets for growth, with China improving, Europe mixed results and Baby Care innovation aimed at offsetting softer demand.

PLUG's bid for $700M in 2025 revenue hinges on strong electrolyzer demand as softer legacy product sales weigh on growth.